The Lens on LEN
The Basics on Injectable Lenacapavir as PrEP
In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention was safe and highly effective against HIV. The product is being tested among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South Africa. No infections were seen among those receiving LEN. This advocates’ primer provides further background on the product and trials, raises key questions, and explores next steps.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!